Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL” - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum for “Simultaneous Targeting of De Novo Pyrimidine Synthesis and ATR Enhances ATF4-Driven Apoptosis in TP53-Deficient Acute Lymphoblastic Leukemia”

  • October 5, 2026

Share

  • 1

    Grünewald and colleagues studied dual blockade of ATR and de novo pyrimidine synthesis in TP53-deficient acute lymphoblastic leukemia.

  • 2

    The study found that this dual blockade promotes ATF4-mediated cell death.

  • 3

    The original article was published in HemaSphere in 2026.

  • 4

    An error in Figure 5's caption incorrectly defined ATR as 'Activating Transcription Factor 4'.

  • 5

    The correct definition of ATR is 'Ataxia Telangiectasia and Rad3-related (ATR) protein'.

Original Source(s)

Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”

  • October 5, 2026

Related Content

Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation

Thyroid Cancer: What Are the Latest Advances in Treatment?

Thyroid cancer is usually a highly treatable malignancy with overall five-year survival rates over 98%. Many patients with thyroid cancer go on to live for several decades after their disease is cured. 

  • by

  • September 29, 2026

  • 6 min
Machine Learning Alone Won’t Take Vibrational Spectroscopy Into the Clinic

Standardized preprocessing, multicenter datasets, external validation, and interpretable models may matter more than further gains in classification accuracy

  • September 30, 2026

  • 3 min